IPA (ImmunoPrecise Antibodies)

Highlights from JPM Healthcare 2024 🧬 It's the "Year of the Antibody" at JPM Healthcare 2024, and we're buzzing with excitement! Dr. Jennifer Bath, CEO of IPA, participated as a panelist in the sold-out discussion titled "Connecting Clusters of Excellence: Europe as Your Gateway to Global Success". Key takeaways: • Leveraging local innovation hubs effectively to create expansive global networks. • Building teams strategically with diverse experts to fuel innovation. • Belgium's favorable tax and IP policies position it as a strategic hub for life sciences. Insightful hands-on contributions from our esteemed fellow panelists Ann Belien, PhD, Youri De Groote, Robert Darwin and John Baekelmans enriched the discussion. Thank you, Health Campus Limburg DC, Yu Chen, Sara Smeets and Roeland Buckinx for organizing this impactful event. Stay connected for more updates from JPM and the forefront of healthcare innovation! Let's start the conversation on leveraging global hubs. https://bit.ly/46XqDLE #JPMHealthcare #JPM24 #Innovation #LifeSciences #GlobalNetworks #AI #ArtificialIntelligence #Antibodies #Biotechnology #healthcampuslimburgDC BioCentury Inc. Sidley Austin LLP flanders.bio Korea Biotechnology Industry Organization (KoreaBIO) Jennifer Bath, Ph.D.

AI is making strides in the development of cancer treatments, with groundbreaking applications for breast cancer. A recent breakthrough using IPA's subsidiary BioStrand LENSᵃⁱ™ model has shown promise by engineering antibodies to elusive tumor proteins in silico. These antibodies target a tumor microenvironment protein with no prior structural data, marking a major advancement in drug discovery. The results have been verified in the lab, offering hope for more effective treatments.    See full article -thanks TechBullion for the highlight: https://lnkd.in/gjF29j4j    As Breast Cancer Awareness Month continues, innovations like LENSᵃⁱ have the potential to reshape outcomes for patients, driving faster and more precise solutions.    #BreastCancerAwareness #LENSai #AI #Innovation #CancerResearch #Oncology #DrugDiscovery Professor Ari Zoltan Quantum Media Group, LLC BioStrand (a subsidiary of IPA)

At PEGS Europe, our proven advanced methods span every essential track: Engineering, Targets, Bispecifics, Immunotherapy, Analytical, Expression, Machine Learning, and Oncology. From AI-driven insights and advanced lab technologies to a pipeline of assets and optimized protein expression, the IPA family of companies empowers teams to tackle complex challenges confidently. Our solutions deliver results at every stage, driven by a commitment to partnership, clinical success and innovation. Don't miss our VHH B cell and advanced rabbit antibody humanization posters in the science hall. We’re setting new standards across all PEGS tracks - designed specifically for you! Stop by booth 1211 #PEGSEurope #mAb #Antibodies #AI #ArtificialIntelligence #DrugDiscovery Ilse Roodink, Ph.D. Nienke Smits

Discover how the future of drug discovery is being redefined. In the latest TechBullion interview, Dr. Jennifer Bath, IPA CEO and President shares how ImmunoPrecise Antibodies is unlocking breakthroughs with AI and advanced wet lab platforms. Our rapid, end-to-end solutions empower researchers to conquer the toughest challenges and innovate faster than ever before. This is biotherapeutics transformed—innovative, precise, and driven by data. See the interview: https://bit.ly/48dC7Nj Ready to explore a customized solution? Let’s tackle the toughest challenges head-on—faster, smarter, and with real impact. Together, we can push the boundaries of what’s possible. Let's connect: https://bit.ly/4dTXVP3 #Biotherapeutics #AI #Innovation #mAb #InSilico #DrugDiscovery #TechBio

NEWS: ImmunoPrecise Antibodies at the AI Driven Drug Discovery Summit USA 2024 This is where the future of AI and drug discovery converge, with top pharma and tech companies in attendance. IPA will lead the conversation with a fireside chat and showcase proven LENSᵃⁱ™ solutions at our booth. Reach out now to secure a meeting now and explore how IPA's biotherapeutic intelligence hub can transform your drug discovery efforts. Don’t miss the opportunity to gain a competitive edge! For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com. #AIDrugDiscovery #PharmaTech #BiotechInnovation #AI #mAb #TechBio #BioTech

How does in silico epitope mapping stack up against traditional X-ray crystallography? In our latest case study, we take an in-depth look at the 6RPS crystal complex and compare both methods. LENSᵃⁱ™'s advanced in silico platform not only matches the accuracy of X-ray crystallography but also delivers high-throughput results in a fraction of the time. This highlights the transformative potential of in silico technologies in optimizing antibody discovery workflows—boosting efficiency, reducing costs, and accelerating timelines. Curious about how this innovative approach can elevate your research? Let's connect: https://lnkd.in/eTBRkN-m #AntibodyDiscovery #EpitopeMapping #InSilico #Biotech #TechBio #DrugDiscovery BioStrand (a subsidiary of IPA)

We’re live at the Festival of Biologics! Visit IPA at booth 346 to explore how we’re driving breakthroughs with our integrated in silico, in vitro, and in vivo platforms. Check out our posters highlighting rabbit therapeutics and VHH discovery, and learn how we’re advancing biotherapeutic innovation in key areas of interest. Our approach is strategically built to serve our clients at the highest level—fast-tracking timelines, reducing costs, and delivering transformative results that drive success. #FestivalOfBiologics #AntibodyDiscovery #Innovation #Biotherapeutics Ilse Roodink, Ph.D. Nienke Smits Edward V.

IPA celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of computational tools and AI in advancing our understanding of protein structures—principles that are central to IPA’s research initiatives. "As IPA continues to enhance LENSᵃⁱ™, our proprietary AI platform, we remain committed to leveraging cutting-edge technologies to unravel complex protein interactions. The Nobel Prize recognition of AlphaFold underscores the growing importance of AI in scientific breakthroughs. At ImmunoPrecise Antibodies, we're dedicated to integrating advanced AI technologies into our workflows, which not only amplifies our capabilities in drug development but also aligns with our mission to pioneer innovative biotherapeutic solutions," said Jennifer Bath, Ph.D. , CEO of ImmunoPrecise Antibodies. Dr. Dirk Van Hyfte also stated “Our HYFT patterns and technology amplifies the power of AlphaFold and other foundational AI models by providing deeper biological context. HYFT identifies key functional and structural motifs within protein sequences, enhancing the precision of AlphaFold's predictions and extending its application in drug discovery." See news: https://lnkd.in/gKGmRNTu Connect for more information: https://lnkd.in/eTBRkN-m BioStrand (a subsidiary of IPA) #TechBio #NobelPrize #Alphafold #DeepMind #HYFT

BioTechX has officially kicked off! We're excited to be at Europe’s largest pharma and healthcare event today and tomorrow, October 9-10, in Basel. Our BioStrand team — Dirk Van Hyfte, Ingrid Brands, and Arnout Van Hyfte — is ready to discuss how our data integration and analytical solutions can accelerate antibody discovery and development. Let’s connect on how we can help you unlock insights from complex datasets and drive innovation. Stop by booth #922 to meet the team and catch our live #demo, where we’ll showcase how our technology can help solve your toughest challenges. Don’t miss this opportunity to see our solutions in action. We looking forward to seeing you! #BioTechX #DataIntegration #mAb #TechBio #AI #Bioinformatics BioStrand (a subsidiary of IPA)

Join us at Festival of Biologics, October 15-17th in Basel, to dive into a platform strategically built to customize your program from start to finish—the hub of biotherapeutic intelligence, where in silico, in vitro, and in vivo innovations come together to accelerate breakthroughs. Discover the ease of integrating in silico capabilities to boost diversity, enhance data-driven decisions, and de-risk the path to the clinic—whether starting fresh or enhancing an existing program. We’ll also be covering growing interest for the versatility of VHH antibodies and the rising interest in developing humanized rabbit antibodies for therapeutic use. See you there - visit booth #346 Connect in advance to hold time to meet with Ilse Roodink, Ph.D., Nienke Smits or Edward V.: https://lnkd.in/eTBRkN-m #FestivalOfBiologics24 #Antibody #mAb #InSilico #Ai #ArtificialIntelligence